EN | TR
E-ISSN: 3061-9947
Clinicopathological Analysis of Patients with Malign Melanoma
PDF
Cite
Share
Request
Original Article
VOLUME: 48 ISSUE: 2
P: 67-72
2015

Clinicopathological Analysis of Patients with Malign Melanoma

Acta Haematol Oncol Turc 2015;48(2):67-72
DOI: 10.5505/aot.2015.63634
Hüsrev Önder Aydın
Olçun Ümit Ünal
Işıl Somalı
İlhan Öztop
Ahmet Uğur Yılmaz
1. Dokuz Eylul University School Of Medicine, Department Of Internal Medicine,ızmir, Turkey
2. Izmir Bozyaka Education And Research Hospital, Department Of Medical Oncology, Izmir, Turkey
3. Dokuz Eylul University School Of Medicine, Department Of Internal Medicine,division Of Medical Oncology, Izmir, Turkey
4. Izmir University School Of Medicine, Department Of Internal Medicine,division Of Medical Oncology, Izmir, Turkey
5.
No information available.
No information available
Received Date: 2015-07-14T13:41:27
Accepted Date: 2015-09-09T20:30:52
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Our aim in this study is to analyse patients with malign melanoma clinicopathologically.

METHODS

In this study, 166 malign melanoma patients that followed by Dokuz Eylul University Hospital Medical Oncology Clinic in years between 1996 and 2011 were evaluated retrospectively.

RESULTS

87 of patients is male, 79 is female. The median age is 52 (21-81). The most common site for malign melanoma is extremity; head, neck and body are less commonly involved. There is no statistically significant difference between primary tumor site and breslow thickness (p=0.109). Breslow thickness and survival are related statistically significant. Average survival time for Breslow thickness between 0 and 2mm is 125,6 months (99-151), 2 and 4 mm is 121,2 months (92-151) and over 4mm is 89 months (68-111) and difference between groups are statistically significant (p=0,012). 1 year survival rate for all patients is 96%, 2 year survival rate is 92.1% and 5 year survival rate is 82.7%. Average survival time is detected as 89,74±6,9 months. Mean survival time for female patients is 108.8 months, 72.9 months for male patients which is statistically significant (P=0,001). There is no significant difference in survival due to melanom primary site (P=0,32). The mean survival time for head-neck malign melanoma is 69.6 months, 114.1 months for body involvement and 82.0 months for extremity involvement.

DISCUSSION AND CONCLUSION

Malign melanoma has the worst progress in all skin cancers and there are several factors affecting the prognosis. The most important prognostic factors detected in this study are breslow thickness, primary tumor site and sex.